April 12, 2017. We support the USPSTF’s efforts to provide updated recommendations on risk assessment, genetic counseling, and genetic testing on BRCA-related cancer, based on quality, up-to-date scientific studies. We hope the review will quantify the benefits and harms of each step starting with screening, in order to help USPSTF to make meaningful recommendations for appropriate subpopulations of women.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Testimony at FDA Meeting on Developing Antibiotics for Bacteria That Rarely Cause Infection
Stephanie Fox-Rawlings, April 13 2017: At an FDA meeting, NCHR explained that developing new antibiotics for rare, low-risk bacteria could do more harm than good by exposing patients to unnecessary side effects, increasing the chances of drug-resistant infections, and diverting resources away from treatments that are truly needed.
Read More »NCHR Testimony at FDA on Opioid, Opana ER
March 14, 2017. Compared with other opioids, reformulated Opana ER, along with its generic counterpart, had the highest injection abuse rates following reformulation.
Read More »NCHR Testimony at FDA Meeting about Abuse-Deterrent Opioid, Roxybond
April 5, 2017. Dr. Megan Polanin testifies at the FDA, stating that there is still abuse potential for the intranasal and intravenous use of RoxyBond in the midst of the nation’s opoiod epidemic.
Read More »NCHR Testimony at FDA on Hangover Treatments
April 4, 2017. Like many public health experts and advocates, we are very concerned about treatments that are marketed and promoted for hangovers that contain either acetaminophen or aspirin.
Read More »